Effectiveness of BNT162b2 Vaccine Against Omicron-SARS-CoV-2 Subvariants in Children 5-11 Years of Age in Quebec, Canada, January 2022 to January 2023.

Razafimandimby, Harimahefa; Sauvageau, Chantal; Ouakki, Manale; Carazo, Sara; Skowronski, Danuta M; De Serres, Gaston

Razafimandimby, Harimahefa; Sauvageau, Chantal; Ouakki, Manale; Carazo, Sara; Skowronski, Danuta M; De Serres, Gaston.

Afiliação

Razafimandimby H; From the Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec, Quebec, Canada.
Sauvageau C; From the Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec, Quebec, Canada.
Ouakki M; Biological Risks, Institut National de Santé Publique du Québec, Quebec, Quebec, Canada.
Carazo S; Department of Social and Preventive Medicine, Faculty of Medicine, Laval University, Quebec, Quebec, Canada.
Skowronski DM; Biological Risks, Institut National de Santé Publique du Québec, Quebec, Quebec, Canada.
De Serres G; Biological Risks, Institut National de Santé Publique du Québec, Quebec, Quebec, Canada.

Pediatr Infect Dis J ; 43(1): 32-39, 2024 Jan 01.

Article em En | MEDLINE | ID: mdl-37922479

Assuntos

COVID-19; Vacinas; Criança; Humanos; Pré-Escolar; Quebeque/epidemiologia; SARS-CoV-2; Vacina BNT162; COVID-19/epidemiologia; COVID-19/prevenção & controle

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas / COVID-19 País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google